Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $3.9 million.

  • Utah Medical Products' Cash from Operations rose 57.05% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 1784.51%. This contributed to the annual value of $14.8 million for FY2024, which is 3343.66% down from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' Cash from Operations is $3.9 million, which was up 57.05% from $2.9 million recorded in Q2 2025.
  • Utah Medical Products' 5-year Cash from Operations high stood at $6.9 million for Q1 2023, and its period low was $2.8 million during Q2 2024.
  • Moreover, its 5-year median value for Cash from Operations was $5.0 million (2021), whereas its average is $4.8 million.
  • In the last 5 years, Utah Medical Products' Cash from Operations surged by 3703.92% in 2023 and then tumbled by 4491.75% in 2024.
  • Over the past 5 years, Utah Medical Products' Cash from Operations (Quarter) stood at $5.0 million in 2021, then increased by 13.9% to $5.7 million in 2022, then decreased by 6.13% to $5.3 million in 2023, then plummeted by 44.92% to $2.9 million in 2024, then skyrocketed by 32.04% to $3.9 million in 2025.
  • Its Cash from Operations was $3.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $4.5 million in Q1 2025.